Class Action: Janssen Adds GSK’s NS5a Inhibitor To Its Hepatitis C Portfolio
This article was originally published in The Pink Sheet Daily
With protease inhibitor simeprevir filed for approval in the U.S., Europe and Japan, and a non-nucleoside polymerase inhibitor in Phase II, adding GSK2336805, also in Phase II, gives the J&J unit three different classes of oral antiviral candidates for HCV.
You may also be interested in...
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Patent litigation settlements have paved the way for Endo’s Par and Teva to secure the first US approvals for generic versions of Novartis’ Afinitor everolimus brand.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.